NLS Pharmaceutics Ltd. Logo

NLS Pharmaceutics Ltd.

Developing therapies for rare CNS disorders, specializing in narcolepsy and sleep-wake issues.

NLSP | US

Overview

Corporate Details

ISIN(s):
CH0523961370 (+1 more)
LEI:
Country:
United States of America
Address:
THE CIRCLE 6, 0 ZURICH
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

NLS Pharmaceutics Ltd. is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system (CNS) disorders. The company is actively developing treatments for sleep-wake disorders, with a particular focus on narcolepsy, aiming to provide safer and more effective therapies to address significant unmet medical needs. NLS Pharmaceutics advances its pipeline of novel CNS therapies and engages in strategic collaborations to develop next-generation treatments, including gene-edited cell therapies.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-04 13:15
Foreign Filer Report
6-K - NewcelX Ltd. (0001783036) (Filer)
English 17.3 KB

Automate Your Workflow. Get a real-time feed of all NLS Pharmaceutics Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for NLS Pharmaceutics Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for NLS Pharmaceutics Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Olema Pharmaceuticals, Inc. Logo
A clinical-stage biopharma developing targeted therapies for women's cancers, focusing on breast cancer.
United States of America
OLMA
OliX Pharmaceuticals, Inc. Logo
Developing RNAi therapeutics for dermatology, ophthalmology, and metabolic diseases via an asiRNA platform.
South Korea
226950
OMEROS CORP Logo
Develops first-in-class therapeutics for challenging diseases with unmet medical needs.
United States of America
OMER
ONCODESIGN Logo
Developing precision oncology solutions for resistant and metastatic cancers.
France
ALONC
Oncodesign Precision Medicine S.A Logo
Develops precision therapies & diagnostics for resistant and metastatic cancers.
France
ALOPM
Oncoinvent ASA Logo
Developing alpha-emitting radiotherapies for treating cancers in the peritoneal cavity.
Norway
OCIN
Oncolys BioPharma Inc. Logo
Developing oncolytic virus therapies and diagnostics for cancer and serious viral infections.
Japan
4588
ONCOLYTICS BIOTECH INC Logo
Developing an immuno-oncolytic virus to treat breast and gastrointestinal cancers.
United States of America
ONCY
Onconetix, Inc. Logo
Develops diagnostics and therapeutics for men's health and oncology markets.
United States of America
ONCO
Oncopeptides Logo
Develops targeted therapies for hematological cancers using peptide-drug conjugate technology.
Sweden
ONCO

Talk to a Data Expert

Have a question? We'll get back to you promptly.